Celcuity IncNASDAQ:CELC
- LAST PRICE15.0400
- TODAY'S CHANGE (%)0.2200 (1.4845%)
- Bid / Lots6.0100/ 2
- Ask / Lots16.9900/ 1
- Open / Previous Close15.0500 / 14.8200
- Day Range
- 52 Week Range
- Volume125,642
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CELC |
|---|---|---|
| 09:32 ET | 1851 | 15.03 |
| 09:36 ET | 100 | 15.03 |
| 09:38 ET | 507 | 15.005 |
| 09:41 ET | 300 | 15.085 |
| 09:54 ET | 909 | 15.085 |
| 10:03 ET | 2874 | 14.98 |
| 10:08 ET | 100 | 14.98 |
| 10:12 ET | 300 | 14.91 |
| 10:14 ET | 200 | 14.905 |
| 10:15 ET | 200 | 14.96 |
| 10:19 ET | 100 | 15 |
| 10:24 ET | 300 | 14.89 |
| 10:26 ET | 265 | 14.91 |
| 10:28 ET | 200 | 14.96 |
| 10:33 ET | 164 | 14.944 |
| 10:35 ET | 212 | 14.95 |
| 10:37 ET | 581 | 14.92 |
| 10:39 ET | 200 | 14.93 |
| 10:42 ET | 300 | 14.91 |
| 10:46 ET | 100 | 14.895 |
| 10:51 ET | 1338 | 14.935 |
| 10:53 ET | 100 | 14.88 |
| 11:02 ET | 100 | 14.92 |
| 11:09 ET | 100 | 14.935 |
| 11:11 ET | 160 | 14.935 |
| 11:15 ET | 700 | 14.93 |
| 11:38 ET | 100 | 14.83 |
| 11:40 ET | 500 | 14.855 |
| 11:42 ET | 1785 | 14.83 |
| 11:47 ET | 1140 | 14.775 |
| 11:49 ET | 100 | 14.775 |
| 11:54 ET | 500 | 14.82 |
| 11:58 ET | 300 | 14.87 |
| 12:00 ET | 100 | 14.89 |
| 12:02 ET | 112 | 14.875 |
| 12:07 ET | 300 | 14.93 |
| 12:09 ET | 329 | 14.92 |
| 12:18 ET | 400 | 14.94 |
| 12:20 ET | 318 | 14.949 |
| 12:27 ET | 500 | 14.93 |
| 12:30 ET | 400 | 14.935 |
| 12:38 ET | 330 | 14.93 |
| 12:39 ET | 100 | 14.99 |
| 12:41 ET | 200 | 15.02 |
| 12:45 ET | 404 | 15.03 |
| 12:48 ET | 507 | 15.04 |
| 12:54 ET | 200 | 15.03 |
| 12:56 ET | 100 | 15.04 |
| 01:01 ET | 289 | 14.96 |
| 01:12 ET | 200 | 14.98 |
| 01:17 ET | 200 | 15.01 |
| 01:19 ET | 100 | 15.005 |
| 01:21 ET | 100 | 15.02 |
| 01:24 ET | 1597 | 14.995 |
| 01:32 ET | 400 | 14.92 |
| 01:35 ET | 100 | 14.955 |
| 01:39 ET | 100 | 14.94 |
| 01:42 ET | 100 | 14.925 |
| 01:51 ET | 1773 | 15 |
| 01:53 ET | 300 | 15.01 |
| 02:02 ET | 225 | 15.025 |
| 02:06 ET | 300 | 15.02 |
| 02:09 ET | 242 | 15.019 |
| 02:18 ET | 100 | 15.025 |
| 02:20 ET | 100 | 15.03 |
| 02:26 ET | 206 | 15.05 |
| 02:31 ET | 657 | 15.05 |
| 02:36 ET | 200 | 14.995 |
| 02:38 ET | 400 | 15.05 |
| 02:40 ET | 100 | 15.06 |
| 02:47 ET | 100 | 15.1 |
| 02:49 ET | 1208 | 15.055 |
| 02:51 ET | 100 | 15.06 |
| 02:58 ET | 100 | 15.065 |
| 03:00 ET | 227 | 15.09 |
| 03:03 ET | 449 | 15.06 |
| 03:05 ET | 100 | 15.06 |
| 03:07 ET | 380 | 15.065 |
| 03:12 ET | 600 | 15.05 |
| 03:14 ET | 200 | 15.04 |
| 03:16 ET | 500 | 15.01 |
| 03:20 ET | 400 | 15.01 |
| 03:21 ET | 188 | 15.01 |
| 03:30 ET | 500 | 15.03 |
| 03:32 ET | 400 | 15.03 |
| 03:34 ET | 100 | 14.965 |
| 03:36 ET | 301 | 14.99 |
| 03:38 ET | 400 | 15 |
| 03:39 ET | 600 | 15.065 |
| 03:41 ET | 100 | 15.065 |
| 03:43 ET | 500 | 15.06 |
| 03:45 ET | 376 | 15.03 |
| 03:48 ET | 152 | 15.03 |
| 03:50 ET | 1575 | 14.98 |
| 03:52 ET | 638 | 14.97 |
| 03:54 ET | 923 | 15.01 |
| 03:56 ET | 205 | 15.01 |
| 03:57 ET | 940 | 15.005 |
| 03:59 ET | 30958 | 15.04 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Celcuity Inc | 548.8M | -5.5x | --- |
Alumis Inc | 545.7M | -2.7x | --- |
Allogene Therapeutics Inc | 545.8M | -1.7x | --- |
Scholar Rock Holding Corp | 565.8M | -3.3x | --- |
Neurogene Inc | 577.0M | -9.9x | --- |
Third Harmonic Bio Inc | 509.2M | -15.3x | --- |
Company Information
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Contact Information
- Headquarters
- 16305 36th Ave N Ste 100MINNEAPOLIS, MN, United States 55446-4285
- Phone
- 763-392-0767
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Brian Sullivan
- Co-Founder, Chief Science Officer, Vice President, Secretary, Director
- Lance Laing
- Chief Financial Officer
- Vicky Hahne
- Chief Commercial Officer
- Eldon Mayer
- Independent Director
- Richard Buller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $548.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 37.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.76 |
EPS | $-2.74 |
Book Value | $5.48 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
